UNISOUND (09678) has announced a significant upgrade to its medical large language model, culminating in the official launch of the industry's first specialized large model, "U2-Med," designed for the integrated healthcare, medical insurance (including commercial insurance), and pharmaceutical sectors. This iteration further solidifies the company's model capabilities in specialized fields, driving continuous technological advancement for high-value token scenarios.
The model is poised to be extensively integrated into the core workflows of digital collaboration across these three sectors, accelerating the expansion of the company's large model business and establishing a long-term, sustainable revenue stream. Built upon the company's U2 foundational model, U2-Med demonstrates significant improvements in computational efficiency and agent execution.
As the industry's first industrial-scale large model integrating capabilities across the entire "three-medicine" chain, U2-Med leverages the company's decade of deep experience in the healthcare field. It breaks down data and operational silos between healthcare, insurance, and pharmaceuticals, supporting their coordinated digital transformation with unified capabilities and comprehensively covering professional task scenarios across the broader healthcare domain.
U2-Med delves into the core business processes of the three sectors, delivering tangible capability and efficiency enhancements for clinicians, insurance professionals, and pharmaceutical practitioners. For doctors, the model offers capabilities such as assisted diagnosis and treatment, medical record generation, and identification of risks in clinical and electronic documentation.
For medical and commercial insurance, the model can accurately identify suspicious cases like off-label drug use, duplicate billing, and excessive treatment, supports DRG/DIP compliance reviews, and helps auditors focus on key verification points. For the pharmaceutical industry, it assists with tasks like pre-screening trial subjects, verifying indications and contraindications, and flagging risks associated with concomitant medication.
This upgrade genuinely enables intelligent coordination across the "clinical diagnosis and treatment—medical insurance payment—pharmaceutical supply" chain, providing a one-stop solution to core industry pain points such as low cross-domain collaboration efficiency, fragmented management, and high labor costs.
In the MedBench evaluation from July 2026, the U2-Med series models ranked first in both the full-modal large model and agent categories. It also leads in the "Three-Medicine Comprehensive Benchmark" oriented towards real-world business, with a non-thinking mode composite score of 89.1 and a thinking mode score of 88.9. Sub-scores include 93.3 for medical record generation and quality control, 94.1 for post-diagnosis and medication management, and 88.8 for medical and commercial insurance tasks.
The evaluation data fully demonstrates that U2-Med is not merely a general medical theory model but a commercial-grade professional model adapted to real-world business processes, where its technical capabilities can be directly translated into industrial value.
Following this upgrade, U2-Med will be deeply embedded into a broader range of business processes across the three sectors. Its "expert-level" capabilities are expected to create higher industrial value while replacing repetitive tasks, thereby unleashing the professional potential of practitioners in these fields.
The company will continue to promote its large-scale implementation in the three-medicine sector, accelerating the positive feedback loop of industrial data accumulation and model iteration. This strategy aims to continuously build higher business barriers and inject long-term momentum for the sustained release and commercial realization of high-value tokens.
The company firmly believes that technological evolution will always follow a path of broad accessibility. The ultimate vision of AGI lies in safeguarding and enhancing widespread public welfare. This aligns with the company's original aspiration from over a decade of dedication to the healthcare field: to transform cutting-edge intelligence into a core driving force that safeguards public health and empowers industrial upgrading, practicing the value of "intelligence for good" through the power of "intelligence upward."
Comments